Sahajanand Medical Technologies Limited (SMT)
சுருக்கம்
Sahajanand Medical Technologies Limited closed at ₹504.65 on 12 Nov 2026. Data as of 12 Nov 2026.
விலை
- சந்தை மதிப்பு
- ₹5,130 கோடி
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 6 நவ. 2026
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 39.09% எதிர் சராசரி 21.63%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 0.1×
- பல்க் & பிளாக் டீல்கள்
- 60 நாட்களில் 10
- விலை வரம்பு
- 1 band close in ~20 sessions
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Sahajanand Medical Technologies Limited reported Q2 FY27 results on 6 Nov 2026: revenue ₹373 Cr, and net profit ₹26.5 Cr; the operating margin was 17.6%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY | QoQ |
|---|---|---|---|
| வருவாய் | ₹373 | — | +6.2% |
| செயல்பாட்டு லாபம் | ₹65.6 | — | +34.9% |
| நிகர லாபம் | ₹26.5 | — | +75.4% |
| EPS (₹) | 2.63 | — | +77.7% |
| செயல்பாட்டு லாப வரம்பு | 17.6% | — | — |
SMT delivery percentage and bulk deals
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 39.09% of the SMT shares traded on NSE were taken to delivery, against the stock's own 20-session average of 21.63%. The price rose 1.34% on that unusually high delivery, the pattern the delivery dashboard labels accumulation. Volume was 0.1 times its average, well below normal. It closed at a price band (circuit) on 1 session in about the last 20. 10 bulk or block deals were reported in SMT in the last 60 days: ₹250 Cr bought and ₹114 Cr sold.
கடந்த 5 அமர்வுகளில் டெலிவரி: 20.5% · 23.1% · 32.8% · 32.7% · 39.1%
| தேதி | பக்கம் | எதிர்தரப்பு | மதிப்பு | விலை | அளவு | வகை |
|---|---|---|---|---|---|---|
| 28 அக். | வாங்கு | Alphagrep Securities Private Limited | ₹36.67 கோடி | ₹509.43 | 719,743 | பல்க் |
| 28 அக். | விற்க | Alphagrep Securities Private Limited | ₹36.57 கோடி | ₹508.15 | 719,743 | பல்க் |
| 28 அக். | வாங்கு | Jump Trading Financial India Private Limited | ₹29.39 கோடி | ₹515.65 | 569,867 | பல்க் |
| 28 அக். | விற்க | Microcurves Trading Private Limited | ₹28.87 கோடி | ₹502.01 | 575,186 | பல்க் |
| 28 அக். | வாங்கு | Microcurves Trading Private Limited | ₹28.85 கோடி | ₹501.64 | 575,186 | பல்க் |
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Sahajanand Medical Technologies (SMT) released the transcript of its first earnings call as a listed company for Q2 and H1 FY27. In Q2 FY27, revenue grew 24.7% YoY to ₹373 crore, while EBITDA surged 36.6% to ₹65 crore with margins expanding 154 bps to 17.6%, and PAT reached ₹26 crore. For H1 FY27, revenue reached ₹725 crore (up 24.9%) and EBITDA rose 43.4% to ₹114 crore, driven by strong growth in structural heart (up ~40%) and European/ROW sales. The cash conversion cycle improved to 128 days from 138 days in FY26, with net debt standing at ₹223 crore.
- Q2 FY27 revenue rose 24.7% YoY to INR 373 crore, with EBITDA up 36.6% to INR 65 crore (17.6% margin)
- H1 FY27 revenue grew 24.9% YoY to INR 725 crore, and normalized PAT grew ~39% excluding a previous-year tax credit of INR 8.7 crore
- Cash conversion cycle shortened by 10 days to 128 days in H1 FY27 compared to 138 days in FY26
- Net debt was INR 223 crore as of September 2026, with net debt to EBITDA around 1x and cash/liquid investments of INR 114 crore
- Telangana facility has significant expansion headroom with DES utilization at only 20% and balloon utilization at 57%
Sahajanand Medical Technologies Limited (SMT) has submitted newspaper clippings confirming the publication of its unaudited financial results for the quarter and half year ended September 30, 2026. The advertisements were published on November 06, 2026, in all editions of Financial Express (English) and the local edition of Gujarat Today (Gujarati). This filing is a statutory compliance requirement under SEBI Listing Regulations.
- Published unaudited financial results for the quarter and half year ended September 30, 2026
- Advertisements released on November 06, 2026
- Carried across all editions of Financial Express and local edition of Gujarat Today
- Submitted under Regulation 30 and Schedule III of SEBI Listing Regulations
Sahajanand Medical Technologies Limited (SMT) has announced the appointment of M/s Amit Jaste & Associates, Company Secretaries, as its Secretarial Auditor. The appointment spans five consecutive financial years, covering FY 2026-27 to FY 2030-31, effective November 05, 2026. The approval was granted during the Board meeting held on November 05, 2026, and remains subject to shareholder approval. The firm brings over 22 years of experience under its founder, holding valid Peer Review Certificate No. 1751/2022.
- Appointment of M/s Amit Jaste & Associates as Secretarial Auditor for a 5-year term
- Term commences from FY 2026-27 through FY 2030-31
- Appointment approved by the Board on November 05, 2026, subject to shareholder approval
- Lead partner brings over 22 years of corporate legal and secretarial experience
Sahajanand Medical Technologies (SMT) announced that its wholly-owned subsidiary, SMT Ireland, will invest up to USD 780,000 in cash to increase its stake in Delaware-based SNP Medical Corp. SMT Ireland already held a 14.15% stake as of September 30, 2026, which will rise to up to 17.19% upon completion. SNP Medical is a medical device startup with 2025 revenue of USD 300,000, and the deal qualifies as a related party transaction because SMT promoter and director Priyanka Cohen serves as a director in SNP. The transaction is expected to conclude by March 31, 2027.
- Investment amount of up to USD 7,80,000 via all-cash consideration by SMT Ireland
- Shareholding in SNP Medical Corp. to increase from 14.15% to up to 17.19%
- Target entity generated turnover of USD 3,00,000 in 2025 (down from USD 5,64,930 in 2023)
- Related party transaction: SMT promoter/director Priyanka Cohen is a director in SNP Medical
- Tentative timeline for transaction completion is March 31, 2027
In its first earnings disclosure post-listing on October 23, 2026, Sahajanand Medical Technologies (SMT) reported its highest-ever quarterly performance in Q2 FY27. Revenue from operations increased 24.7% YoY to ₹3,734 mn, while EBITDA grew 36.6% YoY to ₹656 mn, expanding EBITDA margin by 154 bps to 17.6%. PAT for the quarter rose 26.6% YoY to ₹265 mn. For H1 FY27, revenue reached ₹7,251 mn (+24.9% YoY) and EBITDA stood at ₹1,141 mn (+43.4% YoY), driven by strong expansion in international markets, with RoW growing 37.1% YoY.
- Q2 FY27 revenue rose 24.7% YoY to ₹3,734 mn; H1 FY27 revenue reached ₹7,251 mn (+24.9% YoY)
- Q2 FY27 EBITDA expanded 36.6% YoY to ₹656 mn with a 154 bps margin increase to 17.6%
- Q2 FY27 PAT grew 26.6% YoY to ₹265 mn (7.1% margin)
- RoW region grew 37.1% YoY in H1 FY27, becoming the largest revenue contributor at 40.0% share (₹2,904 mn)
- Vascular Interventions (VI) accounted for 57.9% of H1 revenue, growing 16.1% YoY
CRISIL Ratings has upgraded the bank loan facilities of Sahajanand Medical Technologies Limited (SMTL) from 'CRISIL BBB+/Stable/CRISIL A2' to 'CRISIL A-/Stable/CRISIL A2+' across an enhanced amount of Rs 300 crore. Additionally, ratings for its wholly owned subsidiary SMT Cardiovascular Private Limited were upgraded to 'CRISIL BBB+/Stable' for Rs 50 crore of facilities. The upgrade reflects a strengthening business risk profile, with FY26 operating revenue climbing 18% to Rs 1,214 crore alongside stable operating margins of 13.14%. SMTL's capital structure also improved, with gearing decreasing to 0.43 times and net worth increasing to Rs 633 crore as of March 31, 2026.
- Bank loan facilities rating upgraded to 'CRISIL A-/Stable/CRISIL A2+' on rated amount enhanced to Rs 300 crore (from Rs 280 crore)
- FY26 operating revenue rose 18% to Rs 1,214 crore compared to Rs 1,032 crore in FY25
- Operating margins remained stable at 13.14% in FY26 versus 12.87% in FY25
- Gearing improved to 0.43 times as of March 31, 2026, with net worth expanding to Rs 633 crore
- Wholly owned subsidiary SMT Cardiovascular bank facilities of Rs 50 crore upgraded to 'CRISIL BBB+/Stable'
Sahajanand Medical Technologies Limited (SMT) has scheduled its earnings conference call to discuss Q2 and H1 FY27 financial results on Thursday, November 05, 2026, at 06:30 p.m. IST. The earnings call will follow the financial results announcement planned on the same day. The session will be hosted by Motilal Oswal Financial Services Limited with participation from the Managing Director & CEO and the Chief Financial Officer.
- Earnings conference call scheduled for Thursday, November 05, 2026, from 06:30 p.m. to 07:30 p.m. IST
- Call will review financial results for Q2 FY27 and H1 FY27
- Hosted by Motilal Oswal Financial Services Limited with MD & CEO Bhargav Dhirajlal Kotadia and CFO Amit Kumar Khandelia
Sahajanand Medical Technologies (SMT) has received a summons dated October 16, 2026 (received October 23, 2026) issued under Section 70 of the CGST Act, 2017 by the DGGI Mumbai Zonal Unit. The inquiry calls for verification of books of accounts and evidence concerning GST compliance on reimbursements made to foreign subsidiaries for clinical trials. The company stated that no specific violations are alleged and there is no material financial, operational, or business impact at this stage.
- Summons received under Section 70 of the CGST Act, 2017 from DGGI Mumbai Zonal Unit
- Dated October 16, 2026, and received by the company on October 23, 2026
- Inquiry pertains to GST compliance on reimbursements made to foreign subsidiaries for clinical trials
- No material financial, operational, or business impact identified at this stage
Sahajanand Medical Technologies Limited submitted a regulatory intimation under Regulation 6(1) of SEBI LODR Regulations, 2015. The filing confirms the appointment of Ms. Deepshikha Singhal (ACS - 35992) as Company Secretary & Compliance Officer effective April 01, 2025. The appointment was approved by the Board of Directors at its meeting held on April 16, 2025. This submission is purely procedural and confirms her role as Key Managerial Personnel in whole-time employment.
- Appointment of Ms. Deepshikha Singhal (ACS – 35992) as Company Secretary & Compliance Officer
- Effective date of appointment is April 01, 2025
- Board approval granted at meeting on April 16, 2025
- Filing made under SEBI Listing Regulations 6(1) on October 23, 2026
Sahajanand Medical Technologies Limited has submitted a routine regulatory disclosure under Regulation 30(5) of the SEBI LODR Regulations, 2015. The filing authorizes three Key Managerial Personnel (KMPs) to determine materiality of events and disclose them to stock exchanges. The designated personnel include MD & CEO Bhargav Dhirajlal Kotadia, CFO Amit Kumar Khandelia, and Company Secretary Deepshikha Singhal. The update has no financial or operational impact on the company.
- Disclosure submitted pursuant to Regulation 30(5) of SEBI LODR Regulations, 2015 on October 23, 2026
- Total of 3 Key Managerial Personnel authorized to assess and report material events
- Designated KMPs include MD & CEO Bhargav Dhirajlal Kotadia, CFO Amit Kumar Khandelia, and CS Deepshikha Singhal
- Single contact number provided for general disclosures: 022 49564000
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
